[go: up one dir, main page]

MX2012003500A - Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. - Google Patents

Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c.

Info

Publication number
MX2012003500A
MX2012003500A MX2012003500A MX2012003500A MX2012003500A MX 2012003500 A MX2012003500 A MX 2012003500A MX 2012003500 A MX2012003500 A MX 2012003500A MX 2012003500 A MX2012003500 A MX 2012003500A MX 2012003500 A MX2012003500 A MX 2012003500A
Authority
MX
Mexico
Prior art keywords
hepatitis
methods
cyclic peptide
virus replication
peptide inhibitors
Prior art date
Application number
MX2012003500A
Other languages
English (en)
Inventor
Leonid Beigelman
Brad Buckman
Vladimir Serebryany
Antitsa Dimitrova Stoycheva
Scott D Seiwert
John B Nicholas
Timothy Thrailkill
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of MX2012003500A publication Critical patent/MX2012003500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Las modalidades proporcionan compuestos de las Fórmulas Generales I, la, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, y XII, así como composiciones que incluyen composiciones farmacéuticas que comprenden un compuesto sujeto. Las modalidades además proporcionan métodos de tratamiento que incluyen métodos para tratar la infección por el virus de la Hepatitis C y métodos para tratar la fibrosis hepática, los métodos generalmente comprenden administrar a un individuo que lo necesita una cantidad efectiva de una composición o compuesto sujeto.
MX2012003500A 2009-09-28 2010-09-24 Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. MX2012003500A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24646509P 2009-09-28 2009-09-28
US32425110P 2010-04-14 2010-04-14
US34573710P 2010-05-18 2010-05-18
US34623810P 2010-05-19 2010-05-19
PCT/US2010/050298 WO2011038293A1 (en) 2009-09-28 2010-09-24 Cyclic peptide inhibitors of hepatitis c virus replication

Publications (1)

Publication Number Publication Date
MX2012003500A true MX2012003500A (es) 2012-08-01

Family

ID=43796242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003500A MX2012003500A (es) 2009-09-28 2010-09-24 Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c.

Country Status (19)

Country Link
US (1) US20110081315A1 (es)
EP (1) EP2483290A4 (es)
JP (1) JP2013505952A (es)
KR (1) KR20130026410A (es)
CN (2) CN102741270B (es)
AR (1) AR078462A1 (es)
AU (1) AU2010298028A1 (es)
CA (1) CA2775697A1 (es)
CO (1) CO6531497A2 (es)
EA (1) EA201290128A1 (es)
EC (1) ECSP12011845A (es)
IL (1) IL218766A0 (es)
IN (1) IN2012DN02693A (es)
MA (1) MA33720B1 (es)
MX (1) MX2012003500A (es)
PH (1) PH12012500602A1 (es)
TN (1) TN2012000135A1 (es)
TW (1) TW201124137A (es)
WO (1) WO2011038293A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE602006019323D1 (de) * 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
EP2282762A2 (en) * 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
KR20110075019A (ko) * 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2011107530A2 (en) * 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2801584A1 (en) * 2010-06-07 2011-12-15 Abbvie Inc. Macrocyclic hepatitis c serine protease inhibitors
JP5641663B2 (ja) * 2010-09-10 2014-12-17 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
US20120101032A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN107011339A (zh) * 2011-09-22 2017-08-04 杨森制药公司 用于制备hcv的大环蛋白酶抑制剂的方法和中间体
CN104640442A (zh) 2012-06-14 2015-05-20 巴斯夫欧洲公司 使用取代3-吡啶基噻唑化合物和衍生物防除动物有害物的灭害方法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
MX2015012790A (es) 2013-03-15 2016-02-03 Syngenta Participations Ag Derivados de imidazopiridina activos como microbiocidas.
BR112015021768A2 (pt) 2013-03-15 2016-02-02 Gilead Sciences Inc inibidores do vírus da hepatite c
CN105884779B (zh) * 2015-02-13 2018-06-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
CN108314648A (zh) * 2018-04-12 2018-07-24 苏州康润医药有限公司 4-溴-7-氟异喹啉的合成方法
CN110305018B (zh) * 2019-06-06 2022-07-15 浙江普洛家园药业有限公司 一种3-溴-2-氟硝基苯的制备方法
CN112358447B (zh) * 2020-11-16 2022-04-12 苏州康润医药有限公司 7-氟异喹啉-1-羧酸的合成方法
CN114105800B (zh) * 2021-11-25 2023-09-01 杭州国瑞生物科技有限公司 一种2,3-二氨基苯甲酸甲酯的制备方法
WO2025257072A1 (en) * 2024-06-14 2025-12-18 Syngenta Crop Protection Ag Pesticidally active 2-oxobenzimidazole compounds
CN119143611A (zh) * 2024-11-15 2024-12-17 浙江大学衢州研究院 一种n-异丙基对氟苯胺的连续制备方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8918806D0 (en) * 1989-08-17 1989-09-27 Shell Int Research Chiral compounds,their preparation and use
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
ES2189721T3 (es) 1992-12-29 2003-07-16 Abbott Lab Inhibidores de proteasa retroviral.
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) * 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
CA2405521C (en) * 2000-04-05 2010-06-29 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
NZ521456A (en) * 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE461207T1 (de) * 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
PE20020707A1 (es) * 2000-11-20 2002-08-11 Bristol Myers Squibb Co Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
AU2002305450A1 (en) * 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
KR20040099425A (ko) * 2002-04-11 2004-11-26 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4프로테아제의 억제제
PL215228B1 (pl) * 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
DE60334205D1 (en) * 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60324552D1 (en) * 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
PL199412B1 (pl) * 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EP2143727B1 (en) * 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004282148A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
RS20110578A3 (en) * 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
ATE512971T1 (de) * 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
CN101068828A (zh) * 2004-08-27 2007-11-07 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
WO2006033851A1 (en) * 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Ring-closing metathesis process in supercritical fluid
JP4705164B2 (ja) * 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
PT1912997E (pt) * 2005-07-29 2011-12-19 Tibotec Pharm Ltd Inibidores macrocíclicos do vírus da hepatite c
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2441020C2 (ru) * 2005-08-02 2012-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серинпротеазы
DE602006019323D1 (de) * 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601752B2 (en) * 2005-11-16 2009-10-13 Hoffmann-La Roche Inc. Pyrrolidine derivatives
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en) * 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008502A1 (en) * 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321182B2 (en) * 2006-11-17 2013-11-14 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US20100087382A1 (en) * 2007-02-16 2010-04-08 Boehringer Ingelheim International Gmbh Inhibitors of Hepatitis C NS3 Protease
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
US20090123423A1 (en) * 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
CL2008001274A1 (es) 2007-05-03 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
JP2010526146A (ja) * 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
US7932277B2 (en) * 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
KR20100038417A (ko) * 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
WO2009014730A1 (en) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) * 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
US8163693B2 (en) * 2007-09-24 2012-04-24 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
CN104016970A (zh) * 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
WO2009055335A2 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
CA2709032C (en) * 2007-12-21 2016-02-23 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
EP2282762A2 (en) * 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
ES2458358T3 (es) * 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
EP2323981B1 (en) * 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
US8603737B2 (en) * 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
KR20110075019A (ko) * 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
WO2010059937A1 (en) * 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
US20110064694A1 (en) * 2009-09-09 2011-03-17 Yale University Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) * 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ599133A (en) * 2009-09-15 2013-10-25 Taigen Biotechnology Co Ltd Hcv protease inhibitors
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides

Also Published As

Publication number Publication date
TW201124137A (en) 2011-07-16
EP2483290A4 (en) 2013-05-01
KR20130026410A (en) 2013-03-13
US20110081315A1 (en) 2011-04-07
AU2010298028A1 (en) 2012-04-19
IL218766A0 (en) 2012-06-28
WO2011038293A1 (en) 2011-03-31
ECSP12011845A (es) 2012-06-29
IN2012DN02693A (es) 2015-09-04
CN102741270A (zh) 2012-10-17
CN102741270B (zh) 2015-07-22
MA33720B1 (fr) 2012-11-01
EP2483290A1 (en) 2012-08-08
CN105001302A (zh) 2015-10-28
JP2013505952A (ja) 2013-02-21
CA2775697A1 (en) 2011-03-31
EA201290128A1 (ru) 2013-01-30
AU2010298028A2 (en) 2012-10-04
PH12012500602A1 (en) 2017-08-23
CO6531497A2 (es) 2012-09-28
AR078462A1 (es) 2011-11-09
TN2012000135A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
TN2012000135A1 (en) Cyclic peptide inhibitors of hepatitis c virus replication
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2009142842A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
TW200740851A (en) Novel macrocyclic inhibitors of hepatitis C virus replication
WO2009134616A8 (en) Novel inhibitors of hepatitis c virus replication
WO2008005511A3 (en) Novel inhibitors of hepatitis c virus replication
UA116616C2 (uk) Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
WO2007047146A3 (en) Inhibitors of viral replication
TN2012000358A1 (en) Hepatitis c virus inhibitors
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
MY160130A (en) Hepatitis c virus inhibitors
BR112013028679A2 (pt) inibidores do vírus da hepatite c
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
TN2010000468A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
UA95455C2 (ru) Макроциклические ингибиторы репликации вируса гепатита с
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
CU20090188A7 (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c
CU20090182A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal